Antifungal Resistance RegardingMalassezia pachydermatis: Where Are We Now?

被引:22
|
作者
Peano, Andrea [1 ]
Johnson, Elizabeth [2 ]
Chiavassa, Elisa [1 ]
Tizzani, Paolo [1 ]
Guillot, Jacques [3 ]
Pasquetti, Mario [1 ]
机构
[1] Univ Torino, Dipartimento Sci Vet, Largo Paolo Braccini 2, I-10095 Turin, Italy
[2] Southmead Hosp, Mycol Reference Lab, PHE South West Lab, Bristol BS10 5NB, Avon, England
[3] USC Anses, UPEC, Ecole Natl Vet Alfort, EA Dynamic 7380, F-94704 Maisons Alfort, France
关键词
Malassezia pachydermatis; dog; antifungal resistance; MIC; in vitro susceptibility testing; EPIDEMIOLOGIC CUTOFF VALUES; IN-VITRO SUSCEPTIBILITY; END-POINT DISTRIBUTIONS; GATTII SPECIES COMPLEX; MALASSEZIA-PACHYDERMATIS; OTITIS-EXTERNA; ANTIMICROBIAL SUSCEPTIBILITY; FLUCONAZOLE RESISTANCE; BIOFILM PRODUCTION; CANDIDA-GLABRATA;
D O I
10.3390/jof6020093
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Malassezia pachydermatisis a yeast inhabiting the skin and ear canals in healthy dogs. In the presence of various predisposing conditions it can cause otitis and dermatitis, which are treated with multiple antifungal agents, mainly azole derivatives. This manuscript aims to review the available evidence regarding the occurrence of resistance phenomena in this organism. Various findings support the capacity ofM. pachydermatisfor developing resistance. These include some reports of treatment failure in dogs, the reduced antifungal activity found against yeast isolates sampled from dogs with exposure to antifungal drugs and strains exposed to antifungal agents in vitro, and the description of resistance mechanisms. At the same time, the data reviewed may suggest that the development of resistance is a rare eventuality in canine practice. For example, only three publications describe confirmed cases of treatment failure due to antifungal resistance, and most claims of resistance made by past studies are based on interpretive breakpoints that lack sound support from the clinical perspective. However, it is possible that resistant cases are underreported in literature, perhaps due to the difficulty of obtaining a laboratory confirmation given that a standard procedure for susceptibility testing ofM. pachydermatisis still unavailable. These considerations highlight the need for maintaining surveillance for the possible emergence of clinically relevant resistance, hopefully through a shared strategy put in place by the scientific community.
引用
收藏
页码:1 / 27
页数:26
相关论文
共 50 条
  • [1] Antifungal stewardship in the UK: where are we now?
    Schelenz, Silke
    Agrawal, Samir
    Brady, Aaron
    Kiely, Gillian
    Riaz, Zeshan
    Howes, Emilie
    Felton, Tim
    Micallef, Christianne
    Tyler, Netta
    Bicanic, Tihana
    White, P. Lewis
    JAC-ANTIMICROBIAL RESISTANCE, 2024, 7 (01):
  • [2] Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
    Maubon, Daniele
    Garnaud, Cecile
    Calandra, Thierry
    Sanglard, Dominique
    Cornet, Muriel
    INTENSIVE CARE MEDICINE, 2014, 40 (09) : 1241 - 1255
  • [3] Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
    Danièle Maubon
    Cécile Garnaud
    Thierry Calandra
    Dominique Sanglard
    Muriel Cornet
    Intensive Care Medicine, 2014, 40 : 1241 - 1255
  • [4] Aspirin resistance: Where are we now?
    Abaci, Okay
    Kilickesmez, Kadriye Orta
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2013, 13 (04): : 370 - 373
  • [5] Clopidogrel "Resistance": Where are We Now?
    Qureshi, Zeshan
    Hobson, Alex R.
    CARDIOVASCULAR THERAPEUTICS, 2013, 31 (01) : 3 - 11
  • [6] Antifungal Prophylaxis After Lung Transplantation: Where Are We Now?
    De Mol, Wim
    Bos, Saskia
    Beeckmans, Hanne
    Lagrou, Katrien
    Spriet, Isabel
    Verleden, Geert M.
    Vos, Robin
    TRANSPLANTATION, 2021, 105 (12) : 2538 - 2545
  • [7] Measurements of insulin resistance in hypertension: where are we now?
    Hwu, C-M
    JOURNAL OF HUMAN HYPERTENSION, 2007, 21 (09) : 693 - 696
  • [8] Artemisinin resistance and malaria elimination: Where are we now?
    Hanboonkunupakarn, Borimas
    Tarning, Joel
    Pukrittayakamee, Sasithon
    Chotivanich, Kesinee
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Protease inhibitor resistance update: Where are we now?
    Kim, Rose
    Baxter, John D.
    AIDS PATIENT CARE AND STDS, 2008, 22 (04) : 267 - 277
  • [10] Measurements of insulin resistance in hypertension: where are we now?
    C-M Hwu
    Journal of Human Hypertension, 2007, 21 : 693 - 696